Vanda Pharmaceuticals Files 8-K
Ticker: VNDA · Form: 8-K · Filed: Dec 31, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Vanda Pharma filed an 8-K on 12/30/25, updating corporate info. All good.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on December 30, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, with a business phone number of (202) 734-3400. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Vanda Pharmaceuticals Inc.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not appear to contain material non-public information that would immediately impact the company's stock price.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- December 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2200 Pennsylvania Avenue NW Suite 300E Washington , DC 20037 (address) — Address of principal executive offices
- ( 202 ) 734-3400 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 30, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 30, 2025.
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
What is the telephone number for Vanda Pharmaceuticals Inc.?
The telephone number for Vanda Pharmaceuticals Inc. is (202) 734-3400.
In which U.S. state is Vanda Pharmaceuticals Inc. incorporated?
Vanda Pharmaceuticals Inc. is incorporated in Delaware.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2025-12-30 18:45:43
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20251230.htm (8-K) — 30KB
- vnda8-k12302025exhibit991.htm (EX-99.1) — 26KB
- vandaq32019earningsca_imaga.jpg (GRAPHIC) — 48KB
- 0001628280-25-059155.txt ( ) — 246KB
- vnda-20251230.xsd (EX-101.SCH) — 2KB
- vnda-20251230_lab.xml (EX-101.LAB) — 22KB
- vnda-20251230_pre.xml (EX-101.PRE) — 13KB
- vnda-20251230_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 30, 2025, Vanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUS TM (tradipitant) for the prevention of vomiting induced by motion. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated December 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 30, 2025 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary